Article
Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.
Genes, chromosomes & cancer - 1 Nov 2025
Lin Fengwu, Zhao Miaoqing, Wu Qiang, Wu Wenqi, Wu Xiaoying, Ma Ya, Yin Jiani C, Yang Meng, Gao Min
Abstract excerpt
BACKGROUND: Afatinib, an irreversible pan-ERBB family inhibitor, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) patients with uncommon EGFR activating mutations. However, besides the acquisition of the secondary T790M mutation, other resistance mechanisms to afatinib remain to be explored. MATERIALS AND METHODS: This study retrospectively included 37 NSCLC patients harboring either EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.